Integrating the triglyceride-glucose index with systemic inflammatory biomarkers substantially enhances predictive accuracy for all-cause mortality, cardiovascular death, and diabetes-related fatalities among patients diagnosed with metabolic dysfunction-associated steatotic liver disease.
The underlying clinical challenge addressed by the study relates to metabolic dysfunction-associated steatotic liver disease, designated as MASLD, which is recognized as a prevalent condition closely linked to cardiovascular diseases and type 2 diabetes. The triglyceride-glucose (TyG) index is widely acknowledged as an indicator of insulin resistance. However, its standalone prognostic value for mortality in MASLD remains limited.
To address this limitation, the researchers evaluated whether combining the TyG index with systemic inflammatory markers improves the prediction of all-cause, cardiovascular, and diabetes-related mortality in MASLD patients. Specifically, the investigation evaluated five distinct derivative combinations: TyG-MLR, TyG-NLR, TyG-SIRI, TyG-lgPLR, and TyG-lgSII.
To perform their analysis, the investigators examined data from a large cohort of 7,639 adult participants diagnosed with MASLD in the National Health and Nutrition Examination Survey, known as NHANES. The study incorporated participant data gathered across survey cycles conducted between 2003 and 2018. The mortality follow-up continued until December 31, 2019.
During this median follow-up period of 109 months, the study documented a total of 1,226 deaths from all causes among the 7,639 adult participants. Among these, 408 were cardiovascular-related and 183 were associated with diabetes.
To evaluate correlation and predictive efficacy across the dataset, the research team utilized multivariable Cox regression, Kaplan-Meier survival curves, restricted cubic splines, and receiver operating characteristic curves.
The study results revealed that the associations of individual TyG-inflammatory derivatives with mortality varied by cause of death, demonstrating outcome-specific patterns across the endpoints examined. In dose-response evaluations conducted using restricted cubic splines, relationships for TyG-lgPLR and TyG-lgSII exhibited distinct J-shaped curves when examining all-cause mortality and diabetes-specific mortality. Furthermore, receiver operating characteristic curve analysis revealed that TyG-MLR displayed superior predictive performance for both all-cause mortality and cardiovascular mortality at 1-year, 3-year, and 5-year follow-up intervals, whereas TyG-lgSII emerged as the most accurate predictor for diabetes-related mortality.
In their conclusions, the investigators emphasized that integrating the TyG index with systemic inflammatory biomarkers substantially enhances predictive accuracy for all-cause mortality, cardiovascular death, and diabetes-related fatalities among MASLD patients. The authors highlighted that these combined metabolic-inflammation indicators serve as valuable clinical instruments for individualized risk assessment and may support timely clinical decision-making. Overall, the study provides reliable evidence supporting the clinical application of combined metabolic-inflammation biomarkers to optimize the prognostic stratification of patients diagnosed with MASLD.
Subject of Research: Prognostic value of triglyceride-glucose and inflammatory biomarkers in MASLD mortality
Article Title: Prognostic value of triglyceride-glucose index combined with inflammatory biomarkers for mortality in metabolic dysfunction-associated steatotic liver disease
Article References: Jiang, F., Chen, T., Zhang, J., Hu, K., & Gao, X. (2026). Prognostic value of triglyceride-glucose index combined with inflammatory biomarkers for mortality in metabolic dysfunction-associated steatotic liver disease. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-026-02329-7
Image Credits: AI Generated
DOI: 10.1007/s10238-026-02329-7
Keywords: MASLD, triglyceride-glucose index, systemic inflammation, mortality prediction, cardiovascular mortality, diabetes mortality, NHANES, TyG-MLR, TyG-lgSII, Prognostic, value, triglyceride-glucose
News Source: Ophelia Keating. (November 9, 2026). Combining Triglyceride-Glucose Index With Inflammatory Markers Improves MASLD Mortality Prediction. Scienmag.



